UASSIGNED:尽管在临床上已经确定了单药治疗良性前列腺增生(BPH)的疗效和安全性,未对度他雄胺和非那雄胺的疗效和安全性进行比较.目的系统评价两种药物治疗BPH的有效性和安全性,为临床治疗提供医学依据。
UNASSIGNED:使用电子数据库PubMed对相关文章进行了搜索,Embase,Medline,科克伦图书馆,中国学术期刊全文数据库(CJFD),中国科技期刊数据库(VIP)和万方数据库。根据国际前列腺症状评分(IPSS),比较非那雄胺(对照组)和度他雄胺(实验组)治疗BPH的疗效的随机对照试验(RCT),最大尿流率(Qmax),前列腺体积(PV),生活质量(QOL),严格评估用药后血清前列腺特异性抗原(PSA)水平和药物不良反应(ADR),并考虑纳入.使用RevMan5.4软件进行荟萃分析。
未经评估:共包括8项RCT,共有2,116名患者。荟萃分析表明,与非那雄胺相比,杜他雄胺可有效改善BPH患者的Qmax[均差(MD)=0.32;95%置信区间(CI):(0.01,0.63);P=0.04]。降低IPSS无显著差异[MD=0.13;95%CI:(-0.55,0.82);P=0.70],改善PV[MD=-1.25;95%CI:(-3.30,0.79);P=0.23],降低生活质量[MD=-0.44;95%CI:(-0.93,0.05);P=0.08]和血清PSA水平[MD=-0.04;95%CI:(-0.15,0.07);P=0.50],和ADR的发生[相对风险(RR)=-0.01;95%CI:(-0.05,0.04);P=0.72],差异无统计学意义。
UNASSIGNED:在改善BPH患者的Qmax方面,度他雄胺优于非那雄胺。症状差异无统计学意义,PV,PSA,QOL,或不良反应。度他雄胺是治疗BPH的有效和安全的方法。由于纳入研究的方法学质量和样本量的限制,这一结论需要通过大量且随访时间长的分层RCTS进行验证.
UNASSIGNED: Although the efficacy and safety of monotherapy in the treatment of benign prostatic hyperplasia (BPH) have been established clinically, the efficacy and safety of dutasteride and finasteride have not been compared. The aim was to systematically evaluate the efficacy and safety of the two drugs in the treatment of BPH to provide medical evidence for clinical treatment.
UNASSIGNED: A search of relevant articles was conducted using the electronic databases PubMed, Embase, Medline, Cochrane Library, China Academic Journals Full-text Database (CJFD), Chinese Science and Technology Journal Database (VIP) and Wanfang Database. Randomized controlled trials (RCTs) comparing the efficacy of finasteride (control group) with that of dutasteride (experimental group) in the treatment of BPH with respect to the International Prostate Symptom Score (IPSS), the maximum urinary flow rate (Qmax), prostate volume (PV), quality of life (QOL), serum prostate-specific antigen (PSA) level and adverse drug reactions (ADRs) after medication were strictly evaluated and considered for inclusion. Rev Man 5.4 software was used for the meta-analysis.
UNASSIGNED: A total of 8 RCTs were included, with a total of 2,116, patients. The meta-analysis showed that compared with finasteride, dutasteride can effectively improve the Qmax of patients with BPH [mean difference (MD) =0.32; 95% confidence interval (CI): (0.01, 0.63); P=0.04]. There was no significant difference in reducing IPSS [MD =0.13; 95% CI: (-0.55, 0.82); P=0.70], improving PV [MD =-1.25; 95% CI: (-3.30, 0.79); P=0.23], reducing QOL [MD =-0.44; 95% CI: (-0.93, 0.05); P=0.08] and serum PSA level [MD =-0.04; 95% CI: (-0.15, 0.07); P=0.50], and the occurrence of ADRs [relative risk (RR) =-0.01; 95% CI: (-0.05, 0.04); P=0.72], there was no significant difference.
UNASSIGNED: Dutasteride is better than finasteride in improving the Qmax of patients with BPH. There was no statistically significant difference in symptoms, PV, PSA, QOL, or adverse reactions. Dutasteride is an effective and safe treatment for BPH. Due to the limitations of the methodological quality and sample size of the included studies, this conclusion needs to be verified by stratified RCTS with high volumes and long follow-up times.